Fibrogen_US_Primary_logo_RGB_M01.jpg
FibroGen Reports First Quarter 2022 Financial Results
09 mai 2022 16h01 HE | FibroGen, Inc.
Completed enrollment in ZEPHYRUS-1 Phase 3 study of pamrevlumab in idiopathic pulmonary fibrosis1Q 2022 revenue of $60.8M, growth of 58% vs. 1Q 2021Significant roxadustat volume growth in China in...
Fibrogen_US_Primary_logo_RGB_M01.jpg
FibroGen to Report First Quarter 2022 Financial Results
25 avr. 2022 07h00 HE | FibroGen, Inc.
SAN FRANCISCO, April 25, 2022 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) will announce its first quarter 2022 financial results on Monday, May 9 after the market close. FibroGen will also...
Fibrogen_US_Primary_logo_RGB_M01.jpg
FibroGen Announces Completion of Patient Enrollment in ZEPHYRUS-1, a Phase 3 Clinical Study of Pamrevlumab in Idiopathic Pulmonary Fibrosis
20 avr. 2022 07h00 HE | FibroGen, Inc.
- 356 IPF Patients Enrolled - - Topline Data Anticipated Mid-2023 - SAN FRANCISCO, April 20, 2022 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced completion of patient...
Fibrogen_US_Primary_logo_RGB_M01.jpg
FibroGen to Report Fourth Quarter and Full Year 2021 Financial Results
14 févr. 2022 07h00 HE | FibroGen, Inc.
SAN FRANCISCO, Feb. 14, 2022 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) will announce its fourth quarter and full year 2021 financial results on Monday, February 28 after the market close....
Fibrogen_US_Primary_logo_RGB_M01.jpg
Pamrevlumab Included in Pancreatic Cancer Action Network’s Adaptive Clinical Trial Platform
16 juin 2021 08h00 HE | FibroGen, Inc
SAN FRANCISCO, June 16, 2021 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) announced activation of an experimental arm in the Pancreatic Cancer Action Network's (PanCAN) Precision PromiseSM...
Fibrogen_US_Primary_logo_RGB_M01.jpg
FibroGen Announces First Patient Dosed in ZEPHYRUS, a Phase 3 Clinical Trial of Pamrevlumab for the Treatment of Patients with Idiopathic Pulmonary Fibrosis
22 juil. 2019 07h00 HE | FibroGen, Inc
SAN FRANCISCO, July 22, 2019 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN), today announced dosing of the first patient in the ZEPHYRUS Phase 3 clinical study of pamrevlumab in patients with...
Fibrogen_US_Primary_logo_RGB_M01.jpg
FibroGen Reports Third Quarter 2018 Financial Results
08 nov. 2018 16h02 HE | FibroGen, Inc
—Roxadustat New Drug Applications under Review in China and Japan——Phase 3 Clinical Trials in IPF and Pancreatic Cancer to Initiate in First Quarter 2019——Conference Call Today at 5:00 p.m. Eastern...
Fibrogen_US_Primary_logo_RGB_M01.jpg
FibroGen Reports Second Quarter 2018 Financial Results
07 août 2018 16h02 HE | FibroGen, Inc
Roxadustat U.S. Phase 3 Topline Clinical Data Readout on Track for Fourth Quarter of 2018 Feedback from FDA on Pamrevlumab Pivotal Programs in IPF and in Locally Advanced Unresectable Pancreatic...
FibroGen Presents Latest Data From PRAISE Phase 2b Study of Pamrevlumab in Idiopathic Pulmonary Fibrosis at American Thoracic Society 2018
21 mai 2018 16h00 HE | FibroGen, Inc
SAN DIEGO, May 21, 2018 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN), a biopharmaceutical company, today announced that updated results from the company’s randomized, double-blind,...
Fibrogen_US_Primary_logo_RGB_M01.jpg
FibroGen Granted Orphan Drug Designation for Pamrevlumab in the Treatment of Pancreatic Cancer
21 juin 2017 22h09 HE | FibroGen, Inc.
SAN FRANCISCO, June 21, 2017 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN), a science-based biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has granted...